Avian Pathogenic Escherichia coli: Link to Foodborne Urinary Tract Infections in Humans

Kariyawasam, Subhashinie; Han, Jennifer

doi:10.1007/978-3-030-05011-5_12

Cited by 2 publications

(1 citation statement)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, the treatment of E. coli infections is di cult because of antibiotic-resistant strains. The production of Beta lactamase enzymes(ESBL) in this bacterium makes it resistant to many antibiotics (3,4). Beta lactamases are produced by Gram-negative bacteria and are widely found in the members of the Enterobacteriaceae family.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Comparison The Effect of Single Daily Dose With 48 Hours Interval of Amikacin With Meropenem in Treatment With Urinary Tract Infection With E. Coli: A Clinical Trial Study

Mohsenpur

Azizzadeh

Ghaderi

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: Urinary tract infection is among the most prevalent infections in humans, and E. coli is the most frequent pathogen causing this disease. The production of Beta lactamase enzymes (ESBL) in this bacterium makes it resistant to many antibiotics. The aim of this study was to evaluate a novel method single daily dose of Amikacin at 48 h intervals in a clinical trial This was a double-blind clinical trial study.Material and Methods: The patients were divided into two groups of Intervention (Administration of single daily dose of Amikacin at 48 h intervals Intervals for 1 week 3 doses) and control (Prescription of Meropenem for 1 Week). Results: The mean age of the Intervention group was (46.64±3.89) and control group (46.03±2.38). The frequency of E. coli infection was 61(54%), and that of other infections was 52(46%).Conclusion: The results of our study show the therapeutic effect of single daily dose administration of Amikacin every 48 hours

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Comparison The Effect of Single Daily Dose With 48 Hours Interval of Amikacin With Meropenem in Treatment With Urinary Tract Infection With E. Coli: A Clinical Trial Study

Mohsenpur

Azizzadeh

Ghaderi

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial

Mohsenpour,

Ahmadi,

Azizzadeh

et al. 2024

BMC Res Notes

View full text Add to dashboard Cite

Objectives Urinary tract infections (UTIs) are very common infections in humans, and Escherichia coli (E. coli) is the commonest pathogen leading to UTIs. The generation of beta-lactamase enzymes in this bacterium results in its resistance against many antibiotics. This study compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs with E. coli in a double-blind clinical trial. Methods The current double-blind clinical trial compares three doses of amikacin on alternate days with a daily dose of meropenem in the same period for the treatment of UTIs with E. coli. The patients were assigned to two groups: Intervention (receiving a single dose of amikacin once a day at 48-h intervals for a week, three doses) and control (receiving meropenem for 1/TDS for a week). Results The E. coli infection frequency was 61 (21 cases of non-ESBL and 40 cases of ESBL-positive infections) and the frequency of the other infections was 52 (46%). In the patients with ESBL E. coli infection, ciprofloxacin (21; 70%) showed the highest antibiotic resistance, and nitrofurantoin (33; 91.7%) showed the highest sensitivity. The baseline variables between the control and intervention groups indicated no significant difference (p > 0.05). The frequency of signs and symptoms showed no significant difference between the amikacin and meropenem groups in the first 24 h and the first week. In the second week of follow-up, no clinical signs or symptoms were observed in the two groups. Conclusion The results of this study showed that treatment with amikacin, 1 g q48h, for one week (three doses) has the same result as meropenem, 1 g q8h, for one week (21 doses). The results are the same for the treatment of UTIs with ESBL positive and ESBL negative. Amikacin can be used once every 48 h to treat UTIs, is less expensive and can be administered on an outpatient basis. Trial registration This study was registered in the Iranian Registry of Clinical Trials (IRCT) with ID number: IRCT20170417033483N2 on the date 2018-02-13.

show abstract

Avian Pathogenic Escherichia coli: Link to Foodborne Urinary Tract Infections in Humans

Cited by 2 publications

References 200 publications

WITHDRAWN: Comparison The Effect of Single Daily Dose With 48 Hours Interval of Amikacin With Meropenem in Treatment With Urinary Tract Infection With E. Coli: A Clinical Trial Study

WITHDRAWN: Comparison The Effect of Single Daily Dose With 48 Hours Interval of Amikacin With Meropenem in Treatment With Urinary Tract Infection With E. Coli: A Clinical Trial Study

Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial

Contact Info

Product

Resources

About